| ²é¿´: 427 | »Ø¸´: 2 | |||
| ¡¾ÐüÉͽð±Ò¡¿»Ø´ð±¾ÌûÎÊÌ⣬×÷Õ߻ƻÆ516½«ÔùËÍÄú 5 ¸ö½ð±Ò | |||
[ÇóÖú]
Blood ¹ØÓÚZUMA7Ñо¿½á¹û
|
|||
|
Âé·³°ïæÕÒÒ»ÏÂÔÎÄ ·¢×ÔСľ³æIOS¿Í»§¶Ë |
» ²ÂÄãϲ»¶
323Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸»ªÖÐũҵ071010£¬×Ü·Ö320Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
317Çóµ÷¼Á
ÒѾÓÐ16È˻ظ´
287Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
308Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
08¹¤¿Æ 320×Ü·Ö Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
»·¾³Ñ§Ë¶288Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
293Çóµ÷¼Á
ÒѾÓÐ17È˻ظ´
ÉúÎïѧ071000 329·ÖÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
|
Blood. 2022 Nov 24;140(21):2248-2260Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma ·¢×ÔСľ³æIOS¿Í»§¶Ë |
2Â¥2024-01-23 10:21:49
3Â¥2024-01-23 10:22:09













»Ø¸´´ËÂ¥